Bristol-Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Adolescent Patients

Bristol-Myers Squibb Company (NYSE: BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers ...
Pharmabiz

Bristol Myers Squibb reports positive results from phase 3 SCOUT-HCM trial of Camzyos in adolescents with symptomatic oHCM

Princeton, New Jersey Wednesday, January 14, 2026, 12:00 Hrs [IST] ...
The Cardiology Advisor

Mavacamten Significantly Improves Symptomatic oHCM in Adolescent Population

SCOUT-HCM findings show mavacamten significantly reduces Valsalva LVOT gradient in adolescents with symptomatic oHCM.
Scientific Research Publishing

Boosting Algorithm: An Ensemble Learning Tool for Land Use Land Cover Classification Using Google Alpha Earth Foundations Satellite Embeddings ()

An Ensemble Learning Tool for Land Use Land Cover Classification Using Google Alpha Earth Foundations Satellite Embeddings ...